Gyan Chandra

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19840171 [patent_doc_number] => 12252540 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-03-18 [patent_title] => Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR) [patent_app_type] => utility [patent_app_number] => 17/332578 [patent_app_country] => US [patent_app_date] => 2021-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 92 [patent_figures_cnt] => 163 [patent_no_of_words] => 73991 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 122 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17332578 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451522 [patent_doc_number] => 20230192800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE [patent_app_type] => utility [patent_app_number] => 17/927150 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18451522 [patent_doc_number] => 20230192800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-22 [patent_title] => LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON DERIVATIVE [patent_app_type] => utility [patent_app_number] => 17/927150 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17927150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256830 [patent_doc_number] => 20210369815 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => GLUCOSE RESPONSIVE INSULINS [patent_app_type] => utility [patent_app_number] => 17/327498 [patent_app_country] => US [patent_app_date] => 2021-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17327498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521116 [patent_doc_number] => 12122824 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Anti-TNF antibodies, compositions, and methods for the treatment of active ankylosing spondylitis [patent_app_type] => utility [patent_app_number] => 17/320490 [patent_app_country] => US [patent_app_date] => 2021-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 61141 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 294 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18420148 [patent_doc_number] => 20230174609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-08 [patent_title] => EXTENDED TIME ACTION ACYLATED INSULIN COMPOUNDS [patent_app_type] => utility [patent_app_number] => 17/998090 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10632 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17998090 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18142268 [patent_doc_number] => 20230016112 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => ENGINEERED CD25 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/320118 [patent_app_country] => US [patent_app_date] => 2021-05-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19717359 [patent_doc_number] => 12202882 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-21 [patent_title] => APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/315168 [patent_app_country] => US [patent_app_date] => 2021-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 35 [patent_no_of_words] => 60255 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17315168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505457 [patent_doc_number] => 20220098559 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => ISOLATED GDF TRAP POLYPEPTIDE [patent_app_type] => utility [patent_app_number] => 17/243049 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27964 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17020929 [patent_doc_number] => 20210244800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-12 [patent_title] => Use of Ultrarapid Acting Insulin [patent_app_type] => utility [patent_app_number] => 17/240802 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19042345 [patent_doc_number] => 11931418 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-03-19 [patent_title] => Methods of treating severe inflammation [patent_app_type] => utility [patent_app_number] => 17/240558 [patent_app_country] => US [patent_app_date] => 2021-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 2 [patent_no_of_words] => 17419 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17240558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19439980 [patent_doc_number] => 12090206 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels [patent_app_type] => utility [patent_app_number] => 17/238632 [patent_app_country] => US [patent_app_date] => 2021-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 11 [patent_no_of_words] => 10676 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 460 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17238632 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19916213 [patent_doc_number] => 12291566 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-06 [patent_title] => Anti-TNF antibodies, compositions, and methods for the treatment of active Ankylosing Spondylitis [patent_app_type] => utility [patent_app_number] => 17/237650 [patent_app_country] => US [patent_app_date] => 2021-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 23 [patent_no_of_words] => 51740 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 285 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17237650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17256632 [patent_doc_number] => 20210369617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => LYOPHILIZED MESENCHYMAL STEM CELL DERIVED SECRETOME AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/224068 [patent_app_country] => US [patent_app_date] => 2021-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55534 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17224068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18518535 [patent_doc_number] => 11708416 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-25 [patent_title] => Methods of treating severe insulin resistance by interfering with glucagon receptor signaling [patent_app_type] => utility [patent_app_number] => 17/222236 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 15678 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222236 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18947048 [patent_doc_number] => 11890321 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-02-06 [patent_title] => Method of treating or inhibiting glucose intolerance [patent_app_type] => utility [patent_app_number] => 17/203640 [patent_app_country] => US [patent_app_date] => 2021-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5485 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17203640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18836810 [patent_doc_number] => 11844867 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-19 [patent_title] => Method of delivering insulin into a lumen of the intestinal tract using a swallowable drug delivery device [patent_app_type] => utility [patent_app_number] => 17/202119 [patent_app_country] => US [patent_app_date] => 2021-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 53 [patent_no_of_words] => 24214 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17202119 [rel_patent_id] =>[rel_patent_doc_number] =>)